Are Leadless Pacemakers a Niche or the Future of Device Therapy?∗  by Gold, Michael R.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 1 5 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 2 . 0 2 1EDITORIAL COMMENTAre Leadless Pacemakers a Niche or
the Future of Device Therapy?*
Michael R. Gold, MD, PHDP acemakers were developed in the 1950sprimarily to treat life-threatening transientheart block after cardiac surgery. These were
large external devices connected to epicardial elec-
trodes placed surgically. Although life-sustaining,
these devices were plagued by many problems
including short battery life, lead failures, and infec-
tions, due in part to externalization of part of the
system (1). Interestingly, many of these same issues
are present today with most left ventricular assist
devices, which also are life-sustaining therapies.
With advances in technology, size was reduced signif-
icantly to allow for the ﬁrst implantable pacemaker in
Sweden in 1958. It was more than 50 years ago, in the
early 1960s, that transvenous leads were developed
and ﬁrst used with implantable devices by Parsonnet
et al. (2). These early pacemakers had very limited
functionality and only performed asynchronous pac-
ing. Rapid advances were made with programmable
features, including rate and output, to allow noninva-
sive communication with devices and improved bat-
tery technology to extend pulse generator longevity
beyond the approximate 1-year life span of very early
devices.
Many of the improvements in pacing technology
over the past 5 decades are incremental, but some
have certainly been game-changing or revolution-
ary advances, including dual-chamber pacing to
allow maintenance of atrioventricular synchrony,
rate responsive pacing, and cardiac resynchronization
therapy, with or without deﬁbrillation backup*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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Jude Medical.(Figure 1). Despite these developments, certain prob-
lems have persisted. Complications that result from
the use of implantable devices are the most promi-
nent issue that has persisted over the years. These
complications include acute problems involving the
implantation procedure, such as pneumothorax and
hematoma, as well as more subacute and chronic
problems including infection and lead failure.
Similar problems have plagued the use of all cardiac
implantable electronic devices (CIEDs), although the
solutions have differed.
Signiﬁcant complicationswith implantable cardioverter-
deﬁbrillators (ICDs) have affected their use. Probably
the 2 greatest problems are lead failures and infection.
Although lead recalls have been the most visible of
these issues, all intravascular leads have a disturb-
ingly high failure rate due in part to the chronic stress
placed on them in a beating heart (3). Moreover, the
extraction of leads, either for infection or failure, is
associated with signiﬁcant costs and additional com-
plications. A recent innovation to address this prob-
lem is the development of a subcutaneous ICD. Such a
device avoids the problems associated with intravas-
cular lead use and uses a lead likely to have better
long-term stability (4). However, this ﬁrst-generation
device is not without limitations. It is larger, has a
shorter battery life, lacks remote monitoring capabil-
ities, and has very limited pacing capabilities in-
cluding the lack of antitachycardia pacing. These
limitations will be addressed with further develop-
ment of this technology, but it is already apparent
that the subcutaneous ICD is an important addition to
the treatment options for the prevention of sudden
cardiac death.
Another CIED that has been limited by persistent
lead problems, but with a very different solution, is
implantable hemodynamic monitoring for guiding
the treatment of heart failure (HF). This promising
approach for reducing HF hospitalizations has been
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1506limited by a high incidence of lead failures (5). To
help address this problem, a leadless implantable
monitor was developed and is implanted in the
pulmonary artery, which eliminates complications
associated with a lead or pocket for the device. This
was shown to be very effective for reducing HF ex-
acerbations (6). Again, this ﬁrst-generation device
has limitations, including the lack of continuous
hemodynamic data, limited parameters measured,
and uncertainty regarding the retrievability of the
unit in the long term. Nevertheless, this device
is a novel approach to the challenges of managing
chronic HF.SEE PAGE 1497In this issue of the Journal, Knops et al. (7)
provide intriguing data on the mid-term results of
a leadless pacemaker. This device was designed to
address the complications associated with implant-
able pacemakers. Approximately 8% of pacemaker
implants are associated with acute complications.
There are w65,000 lead failures annually in the
more than 4 million implanted systems worldwide
(8). Accordingly, this is a major problem that has
persisted despite many improvements in lead and
pulse generator design. For this reason, the leadless
pacemaker was developed as a self-contained unit
placed in the right ventricular apex via femoral
vein access. It uses an active ﬁxation mechanism
with an extendable helix and has many contem-
porary features, such as rate response, telemetry,
and data logs. The 1-year data presented in this
paper shows remarkably stable pacing parameters,
including persistent mean pacing thresholds <0.5 V
and sensed ventricular signals (R waves) >10 V.
Based on these data, the projected longevity of
this device is w10 years, even with 100% pacing.
Finally, there were no infections, dislodgments, or
other complications noted after the periprocedural
period.
Despite the outstanding results noted with this
ﬁrst-in-human experience with a leadless pacemaker,
there are limitations of the data that must be
acknowledged. The sample size was very small, with
only 31 subjects followed in the long term. Moreover,
these implantations were performed at a limited
number of very experienced European centers.
Importantly, there were serious implantation com-
plications, including 1 death from the procedure and 1
case of cardiac tamponade. Ongoing larger multi-
center studies in the United States and elsewhere will
provide a more accurate estimate of efﬁcacy and risk
associated with this approach. Nevertheless, these
early results are very encouraging.As with the other novel CIEDs, there are limi-
tations associated with the ﬁrst-generation devices.
For the leadless pacemaker, the most obvious is
the ability to provide only right ventricular pacing.
Neither dual-chamber nor left ventricular pacing,
to allow for cardiac resynchronization therapy, is
available. Remote monitoring is not available, and
the usefulness of the temperature-based rate sensor
has not been established. Undoubtedly, these issues
will be addressed in future generations of leadless
pacemakers.
Predicting the role of this device in pacemaker
therapy is a challenge, as it is for most new devices.
In the United States and most European coun-
tries, w20% to 30% of patients receive ventricular
pacemakers primarily for chronic atrial ﬁbrillation,
and this was largely the population implanted in the
current trial. However, in less developed coun-
tries, this proportion is often $50% (9). In addition,
pacemaker use is limited in many areas of the
world, in part because of the lack of implantation
expertise. The steep learning curve for the leadless
pacemaker implantation and the more common skill
set of femoral vascular access and sheath manipula-
tion suggests that this approach could ﬁll an unmet
need. Consequently, the adoption of this therapy in
such countries could be high, particularly if the
cost is competitive with traditional pacing systems.
There are a number of questions that remain to be
answered regarding this new technology. Will the
device continue to perform at a high level in the long
term and match the reliability of current pacemaker
pulse generators? Is this device retrievable in the
long term, and how are patients managed when
systemic infection develops or the device reaches
elective replacement? Abandoning the device and
implanting a second unit is likely a viable option for
many patients at elective replacement, given the
small size of the unit, 10-year battery life, and mean
age of w70 years for initial implantation. Finally,
will there be any long-term thrombogenic complica-
tions associated with an indwelling right ventricular
pacemaker?
It is easy to envision an important role of leadless
pacing in future CIEDs. The ability to communicate
with a second device placed in the right atrium
would result in dual-chamber pacing capabilities.
Similarly, communication with a subcutaneous ICD
would allow for both bradycardia and antitachycardia
pacing, and it would likely improve rhythm discrim-
ination, reducing oversensing of T waves, myopo-
tentials, or nonbiologic noise associated with such
ICDs. The potential safety of placing a device even
this small in the left ventricle in the absence of
FIGURE 1 The Evolution of Cardiac Implantable Electronic Devices
A pictorial representation of the evolution of cardiac implantable electronic devices including possible future devices. A single-chamber pacemaker with a right
ventricular apical lead and a dual-chamber pacemaker with a second lead in the right atrium are shown. The transvenous implantable cardioverter-deﬁbrillator has an
implantable cardioverter deﬁbrillator (ICD) lead in the right ventricular apex. Cardiac resynchronization therapy is most commonly used with ICD backup. There are
3 leads in the heart with pacing leads in the right atrium and left ventricle through the coronary sinus, as well as an ICD lead in the right ventricle. The subcutaneous ICD
has leads in the subcutaneous tissue outside the heart. The leadless pacemaker has the pacing system fully implanted in the right ventricular apex. Finally, the future
universal device has leadless pacing systems in the right atrium and ventricle, a leadless pacing electrode in the left ventricle, and subcutaneous deﬁbrillation lead
and pulse generator.
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1508anticoagulation is unclear, but the development of
smaller pellets with a transducer could be coupled
with a subcutaneous energy source for cardiac
resynchronization with deﬁbrillation therapy if
appropriate (Figure 1). All of these possibilities point
toward a bright future for leadless pacing with the
likely possibility that the devices of the future will
belargely devoid of intravascular leads, and many will
not require subcutaneous pulse generators. As such,these devices should become the future of pacing in
many types of devices rather than persist as a niche
to compete in the single-chamber pacemaker market.
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